The toll of Alzheimer’s disease on patients, their families, and our society is devastating. Alzheimer’s robs people of their memories, their identities and ultimately their lives. And the cost to society can’t be ignored. According to a new study, “Medicines in Development for Alzheimer’s Disease,” without effective new drugs and other therapies that curtail or … Continue reading “Fighting Alzheimer’s: New Hope in a New Year Through Innovation”
Author: Steve Runnels
Mr. Steve Runnels, MBA (CEO) has more than 26 years of international management experience in the healthcare industry. He has held the position of President and CEO of several start-up biopharmaceutical companies, executive vice president and Board member of publicly traded NeoTherapeutics, Inc. (NEOT: NASDAQ) and Vice President of Marketing and Business Development at Sigma-Aldrich, a Fortune 500 company. He has led drug discovery and in vitro diagnostic product development activities in the therapeutic areas of Central Nervous System, Oncology, Clinical Cytogenetics, Assisted Reproductive Technologies, Immunohematology and Diseases of Bone and Cartilage. He is a Senior Industry Advisor for the National Institutes of Health - Capitalization Assistance Program. Mr. Runnels holds a B.S. in Cell Biology and certification from the American Society of Clinical Pathology as a specialist in Immunohematology and is a Ph.D. candidate in Management.